Vir Biotechnology Signs a License Agreement with Xencor to Utilize Xtend Fc Technology in Antibodies Targeting COVID-19

 Vir Biotechnology Signs a License Agreement with Xencor to Utilize Xtend Fc Technology in Antibodies Targeting COVID-19

Vir Biotechnology Signs a License Agreement with Xencor to Utilize Xtend Fc Technology in Antibodies Targeting COVID-19

Shots:

  • Vir will get non-exclusive access to Xencor’s Xtend Fc technology for extending the half-life of novel Abs that the company is evaluating for treating patients with COVID-19, a disease caused by novel coronavirus SARS-CoV-2
  • Vir will be responsible for research, development, regulatory and commercial activities while Xencor continues to assess the impact of the COVID-19 pandemic on ongoing and planned clinical studies
  • In Aug’2019, the two companies collaborated under which Vir got a non-exclusive license to Xtend technology for utilizing it in developing & commercializing Abs targeting influenza and hepatitis B virus infection

Click here ­to­ read full press release/ article | Ref: Xencor | Image: VIR Biotechnology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post